Related Experiment Videos
[Mexiletine: electrophysiologic effects]
Abstract:
A complete electrophysiological evaluation has been performed before and after the intravenous administration of Mexiletine (M.) (3 mg/Kg/B.W. in 5 minutes) in 28 patients (pts) (6 pts with normal conduction system, 4 pts with sick sinus syndrome, 5 pts with intranodal AV block, 13 pts with bundle branch block, of which 4 with pathological HV and 1 with intrahisian conduction defect). With the exception of a shortening of QTc interval in all the pts, the drug did not significantly affect any other electrophysiological parameters. In the patient with intrahisian conduction defect, M. prolonged the H1 - H2 interval. A statistically significant increase of heart rate has been also observed in a second group of 8 pts with normal sinus function, in whom M. administration was preceded by Atropine (I.V. bolus 0,04 mg/Kg/B.W.). This finding seems to exclude a vagolytic effect of M. The conclusions derived from our experience and pertinent literature are the following: M. is not useful in the treatment of supraventricular arrhythmias because it has negligible effects on atrial and AV nodal conduction; the drug may be safely employed in the treatment of ventricular arrhythmias in pts with atrial and/or AV nodal conduction defects; special caution must be employed when the drug is utilized in pts with sick sinus syndrome and/or with marked intraventricular conduction defects.
Insights
Mexiletine (M.) showed minimal electrophysiological effects in patients, except for QTc shortening. It is not effective for supraventricular arrhythmias but may be safe for ventricular arrhythmias, with caution in specific conduction defects.
Area of Science:
- Cardiology
- Clinical Electrophysiology
- Pharmacology
Context:
- Mexiletine is an antiarrhythmic drug.
- Electrophysiological evaluations are crucial for assessing cardiac conduction.
- Various cardiac conduction abnormalities necessitate careful drug selection.
Purpose:
- To evaluate the electrophysiological effects of intravenous Mexiletine.
- To determine Mexiletine's efficacy and safety in different patient groups with cardiac conduction defects.
Summary:
- Intravenous Mexiletine (3 mg/Kg/B.W.) administration in 28 patients resulted in QTc interval shortening.
- No significant changes were observed in other electrophysiological parameters, except for a prolonged H1-H2 interval in one patient with intrahisian conduction defect.
- Mexiletine did not demonstrate significant effects on atrial or AV nodal conduction, suggesting limited utility for supraventricular arrhythmias.
Impact:
- Mexiletine may be safely used for ventricular arrhythmias in patients with atrial and/or AV nodal conduction defects.
- Caution is advised when using Mexiletine in patients with sick sinus syndrome or significant intraventricular conduction defects.
- The findings guide the clinical application of Mexiletine in managing cardiac arrhythmias.